摘要
男性性腺功能减退症是由于雄激素缺乏引起的一种临床综合征,睾酮替代治疗(TRT)是其首选治疗方法.但对于既往有前列腺癌病史的患者,TRT的应用一直存在争议.近年来,文献报道了不同阶段前列腺癌患者接受TRT的安全性研究,包括癌前病变期,主动监测、根治性治疗后及进展期前列腺癌.本文回顾这些文献并对TRT在前列腺癌患者中应用的安全性研究进展进行综述.
Hypogonadism in men is a clinical syndrome caused by androgen deficiency,for whom testosterone replacement therapy(TRT)is the preferred treatment.However,the use of TRT has been controversial in patients with a previous history of prostate cancer.In recent years,studies on the safety of TRT in patients with prostate cancer at different stages have been reported,including pre-cancerous stage,active surveillance,post-radical treatment and advanced prostate cancer.This article reviews the literatures and the progress in the application safety of TRT in patients with prostate cancer.
作者
汪奇波
朱绍兴
WANG Qi-bo;ZHU Shao-xing(Department of Urology,Cancer Hospital of the University of Chinese Academy of Sciences,Zhejiang Province,Hangzhou310022,China)
出处
《中国当代医药》
2020年第8期16-18,共3页
China Modern Medicine
基金
浙江省自然科学基金资助项目(LY16H160034)。
关键词
前列腺癌
性腺功能减退症
睾酮
替代治疗
Prostate cancer
Hypogonadism
Testosterone
Replacement therapy